ResearchSpace

Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration

Show simple item record

dc.contributor.author Semete, B
dc.contributor.author Booysen, L
dc.contributor.author Kalombo, Lonji
dc.contributor.author Ramalapa, B
dc.contributor.author Hayeshi, R
dc.contributor.author Swai, HS
dc.date.accessioned 2012-04-16T09:49:42Z
dc.date.available 2012-04-16T09:49:42Z
dc.date.issued 2012-03
dc.identifier.citation Semete, B, Booysen, L, Kalombo, L, Ramalapa, B, Hayeshi, R and Swai, HS. 2012. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. International Journal of Pharmaceutics, vol. 424(1-2), pp 115-120 en_US
dc.identifier.issn 0378-5173
dc.identifier.uri http://www.sciencedirect.com/science/article/pii/S0378517311011732
dc.identifier.uri http://hdl.handle.net/10204/5761
dc.description Copyright: 2011 Elsevier. This is the post-print version of the work. The definitive version is published in the International Journal of Pharmaceutics, vol. 424(1-2), pp 115-120 en_US
dc.description.abstract The surface of nanoparticles is often functionalised with polymeric surfactants, in order to increase systemic circulation time. This has been investigated mainly for intravenously administered nanoparticles. This study aims to elucidate the effect of surface coating with various concentrations of polymeric surfactants (PEG and Pluronics F127) on the in vitro protein binding as well as the tissue biodistribution, post oral administration, of PLGA nanoparticles. The in vitro protein binding varied depending on the polymeric surfactant used. However, in vivo, 1% PEG and 1% Pluronics F127 coated particles presented similar biodistribution profiles in various tissues over seven days. Furthermore, the percentage of PEG and Pluronics coated particles detected in plasma was higher than that of uncoated PLGA particles, indicating that systemic circulation time can also be increased with oral formulations. The difference in the in vitro protein binding as a result of the different poloxamers used versus similar in vivo profiles of these particles indicates that in vitro observations for nanoparticles cannot represent or be correlated to the in vivo behaviour of the nanoparticles. Our results therefore suggest that more studies have to be conducted for oral formulations to give a better understanding of the kinetics of the particles. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.relation.ispartofseries Workflow;8762
dc.subject Nanoparticles en_US
dc.subject Nanotechnology en_US
dc.subject Polymeric surfactants en_US
dc.subject Protein binding en_US
dc.subject PEGylated PLGA nanoparticles en_US
dc.title Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration en_US
dc.type Article en_US
dc.identifier.apacitation Semete, B., Booysen, L., Kalombo, L., Ramalapa, B., Hayeshi, R., & Swai, H. (2012). Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. http://hdl.handle.net/10204/5761 en_ZA
dc.identifier.chicagocitation Semete, B, L Booysen, Lonji Kalombo, B Ramalapa, R Hayeshi, and HS Swai "Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration." (2012) http://hdl.handle.net/10204/5761 en_ZA
dc.identifier.vancouvercitation Semete B, Booysen L, Kalombo L, Ramalapa B, Hayeshi R, Swai H. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. 2012; http://hdl.handle.net/10204/5761. en_ZA
dc.identifier.ris TY - Article AU - Semete, B AU - Booysen, L AU - Kalombo, Lonji AU - Ramalapa, B AU - Hayeshi, R AU - Swai, HS AB - The surface of nanoparticles is often functionalised with polymeric surfactants, in order to increase systemic circulation time. This has been investigated mainly for intravenously administered nanoparticles. This study aims to elucidate the effect of surface coating with various concentrations of polymeric surfactants (PEG and Pluronics F127) on the in vitro protein binding as well as the tissue biodistribution, post oral administration, of PLGA nanoparticles. The in vitro protein binding varied depending on the polymeric surfactant used. However, in vivo, 1% PEG and 1% Pluronics F127 coated particles presented similar biodistribution profiles in various tissues over seven days. Furthermore, the percentage of PEG and Pluronics coated particles detected in plasma was higher than that of uncoated PLGA particles, indicating that systemic circulation time can also be increased with oral formulations. The difference in the in vitro protein binding as a result of the different poloxamers used versus similar in vivo profiles of these particles indicates that in vitro observations for nanoparticles cannot represent or be correlated to the in vivo behaviour of the nanoparticles. Our results therefore suggest that more studies have to be conducted for oral formulations to give a better understanding of the kinetics of the particles. DA - 2012-03 DB - ResearchSpace DP - CSIR KW - Nanoparticles KW - Nanotechnology KW - Polymeric surfactants KW - Protein binding KW - PEGylated PLGA nanoparticles LK - https://researchspace.csir.co.za PY - 2012 SM - 0378-5173 T1 - Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration TI - Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration UR - http://hdl.handle.net/10204/5761 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record